Register for our free email digests:
David Wallace
Executive Editor
Generics Bulletin Managing Editor Dave Wallace has nearly 10 years experience of reporting on the global generic, biosimilar, value-added and OTC medicines industries. Bringing his background and education in law to bear on industry litigation - as well as national legislative and regulatory affairs - he also keeps a close eye on corporate strategy, personnel moves, and product pipelines. A regular delegate to industry events and conferences, he has a particular interest in local market developments, maintaining close links with national industry representatives. He also organizes and judges the annual Global Generics & Biosimilars Awards. A French speaker, Dave enjoys music - with a love of the piano - and visual arts.
Latest From David Wallace
Stada Will Continue To Invest To Drive Growth
After a 12-month period that has seen Stada make significant investments in generics, biosimilars and consumer healthcare, CEO Peter Goldschmidt tells Generics Bulletin that the firm does not intend to stop there, as it pursues both organic and inorganic growth opportunities.
AAM Welcomes Biosimilar Access Bill
A US bill aimed at promoting biosimilars by encouraging greater prescribing rates and creating a shared savings demonstration program for biosimilars has been warmly welcomed by the AAM.
Remdesivir Compulsory Licensing Is A Dead End For Europe
In the wake of the revelation that the US has secured rights to almost all of Gilead’s remdesivir supplies through September 2020, compulsory licensing had been raised as a possible way for countries to procure versions of the COVID-19 treatment. However, Medicines for Europe has cautioned that the procedure will not be practical to apply in Europe.
Argentina's CILFA Joins IGBA
Argentina’s off-patent industry association, CILFA, has joined global body the IGBA as an associate member.
Glenmark Pushes Back On US Price-Fixing Charges
Glenmark has issued a forceful rebuttal over US price-fixing charges being pursued by the country’s Department of Justice covering drugs such as pravastatin.
Japan Approves First Humira Biosimilar
Japan has approved its first biosimilar rival to Humira. Mylan is set to market the Fujifilm Kyowa Kirin Biologics adalimumab biosimilar, having already launched the product as Hulio in Europe.